Plus a novel argument that suggests that U.S. drug prices aren’t as high as usually assumed
And a new study says that 340B is driving up hospital costs for employers by $36 billion (!)
Plus Noom plugs into Lilly’s pharm-to-table ecosystem
And when it comes to obesity meds, we should listen to Axl: All we need is just a little patience
Plus ... how a wildly speculative NEJM piece on ‘pharm to table’ misses the point
Plus some links on tariffs and a new study that looks at 340B margins
And a new paper underscores how tough it can be to talk about launch prices
Plus a bunch of items that I missed last week on everything from a row in the UK to pricing decisions in an increasingly competitive rare disease
And retail pharmacy is in deep trouble. Could a new effort from Optum reverse the trend?
Plus a new filing from pharma companies in the latest legal battle over the IRA
And is the government getting wobbly on its objections to the 340B rebate model?
And Dr. Oz had some worthwhile thoughts on PBMs and drug pricing last week
